Claims for Patent: 4,849,353

Summary for Patent: 4,849,353

Title:	Immunocapture of enzyme inhibitor, enzyme complexes and uses thereof
Abstract:	This invention relates to methods for detecting, identifying and quantifying enzymes, for example, human proteolytic enzymes. The method broadly comprises forming an immobilized or insoluble complex comprising enzyme, enzyme inhibitor and enzyme inhibitor-antibody reactive site and then detecting and identifying, preferably quantitatively, one or more enzymes bound to the complex, or one or more inhibitor antibodies bound to the complex to indirectly detect one or more bound enzyme. In a preferred embodiment, a matrix, e.g. solid or semisolid surface or permeable matrix, has affixed thereto enzyme inhibitor-antibody or an immonologically active (inhibitor binding) fragment of such an antibody. This insoluble enzyme inhibitor interacting matrix is then contacted with The invention described herein was at least in part made in the course of work under a grant or award from the Department of Health, Education and Welfare (Grant No. HL 18828, Department of Health & Human Services).
Inventor(s):	Harpel; Peter C. (New York, NY)
Assignee:	Cornell Research Foundation, Inc. (Ithaca, NY)
Application Number:	06/712,473
Patent Claims:	1. A method of analyzing biological fluid for naturally occurring proteolytic enzyme inhibitor-proteolytic enzyme complexes which comprises: (a) forming an insoluble immobilized immunocaptured naturally occurring proteolytic enzyme inhibitor-proteolytic enzyme complex comprising proteolytic enzyme, naturally occurring proteolytic enzyme inhibitor present in said biological fluid, and enzyme inhibitor antibody or an inhibitor reactive fragment thereof, and (b) detecting the enzyme or enzyme inhibitor-enzyme complex in the insoluble immobilized immunocaptured complex. 2. The method of claim 1 wherein immobilized naturally occurring proteolytic enzyme inhibitor-proteolytic enzyme complex is affixed to a solid or semisolid matrix by means of the inhibitor antibody or active fragment thereof. 3. The method of claim 1 or 2 wherein the enzyme inhibitor is .alpha..sub.2 -macroglobulin. 4. The method of claim 1 or 2 wherein the enzyme inhibitor is .alpha..sub.2 -macroglobulin and the matrix is an agarose gel. 5. The methods of claims 1 or 2 wherein the biological fluid is a human biological fluid. 6. A method which comprises: (a) affixing an enzyme inhibitor antibody against a naturally occurring proteolytic enzyme inhibitor or inhibitor reactive fragment thereof to a solid or semi-solid matrix (b) contacting the resultant insoluble inhibitor reactive matrix with a biological fluid to capture naturally occurring enzyme inhibitor-enzyme complex from said fluid (c) analytically determining the identity or quantity of the captured enzyme. 7. The method as in claim 6 wherein the captured naturally occurring proteolytic enzyme inhibitor-proteolytic enzyme complex is enzymatically reactive and the analytical determination comprises reacting the insoluble immobilized complex against substrates reactive to the captured enzyme. 8. The method as in claim 6 wherein the enzyme inhibitor is .alpha..sub.2 -macroglobulin. 9. The method as in claim 6 wherein the insoluble captured naturally occurring proteolytic enzyme inhibitor-proteolytic enzyme complex is not enzymatically reactive and the analytical determination comprises reacting the immobilized complex with a detection facilitating material which reacts with a site specific to the bound enyzme or the enzyme inhibitor-enzyme complex. 10. A method of analyzing biological fluid for naturally occurring proteolytic enzyme inhibitor-proteolytic enzyme complexes which comprises: (a) forming an insoluble immobilized immunocaptured reaction product of a naturally occurring proteolytic enzyme inhibitor-proteolytic enzyme complex present in said biological fluid and an antibody against said naturally occurring inhibitor or a reactive fragment of said antibody and (b) detecting the enzyme or enzyme inhibitor-enzyme complex in the immobilized immunocaptured complex. 11. The method of claim 10 wherein the proteolytic enzyme is selected from the group consisting of plasmin, thrombin, kallikrein, Cl, factor X.sub.a, Hageman factor, trypsin, leukocyte elastase, pancreatic elastase, chymotrypsin, collagenase, cathespin G and cathespin B. 12. The method as in claims 10 or 11 wherein the maturally occurring proteolytic enzyme inhibitor is selected from the group consisting of alpha 2-plasmin inhibitor, alpha 2-macroglobulin, alpha 1-anti-trypsin, Cl inhibitor and antithrombin-heparin cofactor. 13. The method of claim 10 wherein the naturally occurring proteolytic enzyme inhibitor is .alpha..sub.2 plasmin inhibitor, wherein the proteolytic enzyme is plasmin, and wherein the bound .alpha..sub.2 plasmin inhibitor-plasmin complex is measured by measuring complexed plasmin.

Details for Patent 4,849,353

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2039-03-29